Latest information on COVID-19
Support teaching, research, and patient care.
1. My recent clinical research involved being a recipient of Stanford’s Maternal and Child Health Research Institute (MCHRI) Clinician Educator Grant Program to study "Barriers to Optimal Breast Milk Provision and Successful Breastfeeding in the NICU Setting".<br/>2. I also serve as the PI for the multicenter study of transcutaneous bilirubin use in extremely preterm infants less than 30 week gestation in California NICU's.<br/><br/>3. My previous clinical research projects include being the site PI and a recipient of UCSF sub-award grant for a Multicenter clinical research study-PDA Tolerate Trial- ( PDA: TO LEave it alone or Respond And Treat Early - Trial)Trial of Early Treatment of the patent ductus arteriosus versus Conservative Treatment. <br/><br/>I have been interested in clinical research on studying factors determining patent ductus arteriosus closure in preterm infants. My initial research project looked at the factors determining closure of a PDA in preterm infants and examined the role of prophylactic indomethacin treatment in achieving ductal closure. The study found that prophylactic indomethacin improved the rate of permanent ductus closure by increasing the degree of initial constriction. Prophylactic indomethacin did not affect the remodeling process, nor did it alter the inverse relationship between infant maturity and subsequent reopening. Even when managed with prophylactic indomethacin, the rate of ductus reopening remained unacceptably high in the most immature infants. By providing evidence and clinical solutions, this body of work has been widely cited and informed practical applications for clinicians who care for preterm infants.<br/>My interest in PDA in preterm infants extended to research in assessing the safety and efficacy of medications used in the management of PDA. We looked at Mednax National group’s extensive database and identified infants <28weeks gestational age discharged from neonatal intensive care units who were treated with indomethacin or ibuprofen between postnatal days 2 and 14. We observed similar effectiveness and safety profiles for indomethacin and ibuprofen in the medical management of PDA in premature infants.<br/>In an effort to study parental knowledge and education in caring for very low birth weight infants, we collaborated with investigators at Center for Policy, Outcomes and Prevention research. We specifically focused on Retinopathy of prematurity (ROP) which is a disorder of the developing retina that occurs in two-thirds of infants born preterm or very low birth weight (VLBW). Use of visual modalities, rather than standard verbal or written instructions, may improve parents’ understanding and adherence with recommended outpatient ROP care.